Merck Millipore hopes the promise of reducing the number of experiments needed during process development will win customers for its new MAb development kit.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
R&D software firm Accelrys says it will speed up the pharma QA/QC process and reduce the compliance risk ten-fold through its $35m takeover of VelQuest.
In September Outsourcing-pharma held Patient Recruitment Outsourcing (PRO) in Boston, bringing together the movers and shakers in the recruitment sector. Robert Loll, vice president of business development, shares his thoughts on the event with a particular...
in-PharmaTechnologist presents its round-up of the latest appointments in the pharmaceutical industry, including news from BIO, Natrix, Amarantus and 3M.
Retrofitting stainless steel plants with single-use systems is driving a “paradigm shift” in drug production but creates logistical problems, an AAPS panel said.
Researchers have called for closer monitoring of pharma manufacturing discharges after detecting endocrine disruption in fish downstream from a Sanofi plant.
DSM Biologicals has launched a new production method designed to streamline downstream processing during biopharmaceutical manufacturing that, it claims, makes making mAB-based drugs more cost effective.
Catalent Pharma Solutions and German expression system developer Cevec Pharmaceuticals have partnered to create a cell development service that, they claim, will help drugmakers generate stable lines faster.
How have single-use technologies changed drug production? How do you dispose of a disposable technology? What will drive the market going forward? EMD Millipore answered these questions and more at Interphex 2011.
Ingenuity Systems, the California, US-based life sciences software developer has announced a research collaboration with US contract research organisation (CRO), Covance.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
Beta-Pro is addressing rising demands from drug discovery and research institutes in the hepatocyte market by expanding its site at the University of Virginia Research Park, US, with a new GLP facility.
SAFC and Novozymes Biopharma have agreed to extend their partnership by ten years for the exclusive distribution of LONG R3 growth factor, used for industrial cell culture applications.
Pfenex has won a US federal contract to use its expression technology for the rapid, cost-effective production of “unprecedented” amounts of anthrax vaccine.
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Millipore is targeting protein manufacturers with a new chromatography resin that, the firm claims, offers flexibility and high throughput with a small manufacturing footprint.
Water used by pharmaceutical manufacturing facilities is being released into the environment with drug concentrations that are up to 1000 times higher than normal according to a study conducted by the US Geological Survey (USGS).
Xcellerex is building a second cGMP FlexFactory biomanufacturing facility to support clients transitioning to their own plants and provide contract manufacturing services.
Ampac Flexibles continues to utilise its High-Speed (HS) Laminate technology by launching its laminate films – a product, which the makers claim will heat seal at temperatures 40 degrees lower than standard laminate materials.
DSM Biologics says combining its XD platform with newly-acquired Rhobust chromatography platform will create high yield, low cost bio-manufacturing option.
BioStorage Technologies has allied with Biomatrica to offer clients the option to store biological samples at room temperature, which reduces costs and energy use while maintaining stability.
Dr Reddy’s has made a “significant investment” in an mPEG alcohol production facility in Mexico to strengthen its presence in a sector it believes is on the rise.
SAFC Biosciences hopes Ex-Cell Antifoam, its new foam control product for cell culture bioreactors, will work the biomanufacturing sector into a lather.
Canadian biologics CMO BioVectra has been contracted to make trial supplies of the candidate cancer treatment Prolanta by US biopharmaceutical firm Oncolix.
US CMO Florida Biologix (FB) says its new contract with America Stem Cell (ASC) shows that demand for trial-phase biologics manufacturing is starting to recover.
Demand for downstream processing products from biotechs drove the continued recovery of Millipore’s bioprocessing division in Q2 but operating income remained flat.
BASF and Sinopec are to invest $1.4bn (€1bn) in expanding their Chinese specialty chemical joint venture, adding 10 plants and increasing capacity at three existing sites.
Millipore has ramped up capacity for its Mobius range of single use bio-processing and manufacturing technologies with a new purpose built production facility in Danvers, Massachusetts.
CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
Wacker has brought its expanded cyclodextrin facility online following its $21m (€15m) expansion, which has significantly increased capacity in response to growing demand for the excipient.
